| Literature DB >> 33753401 |
Arjee Javellana Restar1, Harry Jin2, Brooke Jarrett2, Tyler Adamson3, Stefan David Baral2, Sean Howell4, S Wilson Beckham5.
Abstract
BACKGROUND: We characterised the impact of COVID-19 on the socioeconomic conditions, access to gender affirmation services and mental health outcomes in a sample of global transgender (trans) and non-binary populations.Entities:
Keywords: COVID-19; mental health & psychiatry; public health
Mesh:
Year: 2021 PMID: 33753401 PMCID: PMC7985976 DOI: 10.1136/bmjgh-2020-004424
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Hypothesised structural equation model with two proposed tests for mediation analyses. Error variance terms for measured variables are shown as ε. Model is adjusted for gender identity, age, migrant status, WHO region, education and level of socioeconomic status.
Reporting checklist for a cross-sectional study design using STrengthening the Reporting of OBservational studies in Epidemiology statement
| Item no. | Recommendation | Page no. | |
| ( | 1–3 | ||
| ( | 3–34 | ||
| Background/Rationale | 2 | Explain the scientific background and rationale for the investigation being reported. | 5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses. | 5 |
| Study design | 4 | Present key elements of study design early in the paper. | 5–6 |
| Setting | 5 | Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow-up and data collection. | 5–6 |
| Participants | ( | 5–6 | |
| ( | 5–6 | ||
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders and effect modifiers. Give diagnostic criteria, if applicable. | 6–7 |
| Data sources/measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | 6–7 |
| Bias | 9 | Describe any efforts to address potential sources of bias. | 6–7 |
| Study size | 10 | Explain how the study size was arrived at. | 6–7 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. if applicable. Describe which groupings were chosen and why. | 6–7 |
| Statistical methods | 12 | ( | 7 |
| ( | 7 | ||
| ( | 7 | ||
| ( | 7 | ||
| ( | 7 | ||
| Participants | 13 | (a) Report number of individuals at each stage of study—eg, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up and analysed. | 7–8 |
| (b) Give reasons for non-participation at each stage. | n/a | ||
| (c) Consider use of a flow diagram. | n/a | ||
| Descriptive data | 14 | (a) Give characteristics of study participants (eg, demographic, clinical, social) and information on exposures and potential confounders. | 7–8 |
| (b) Indicate number of participants with missing data for each variable of interest. | 12 | ||
| (c) | n/a | ||
| Outcome data | 15 | n/a | |
| 7–8 | |||
| 7–8 | |||
| Main results | 16 | ( | 7–8 |
| ( | 7–8 | ||
| ( | n/a | ||
| Other analyses | 17 | Report other analyses done—eg, analyses of subgroups and interactions, and sensitivity analyses. | n/a |
| Key results | 18 | Summarise key results with reference to study objectives. | 8–9 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | 9 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies and other relevant evidence. | 8–9 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results. | 9–10 |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based. | 10 |
Sample characteristics by mental health outcomes (n=849)
| Total sample N (%) or M (SD) | Anxiety | Depression | |||||
| Screened positive | Screened negative | χ2 or t-test | Screened positive | Screened negative | χ2 or t-test | ||
| Total | 849 (100.00%) | 389 (45.82%) | 460 (54.18%) | 432 (50.88%) | 417 (49.12%) | ||
| Demographic (control) variables | |||||||
| Gender | |||||||
| Non-binary | 583 (68.67) | 248 (63.75) | 335 (72.83) | 0.017* | 276 (63.89) | 307 (73.62) | 0.004** |
| Trans feminine | 233 (27.44) | 124 (31.88) | 109 (23.70) | 140 (32.41) | 93 (22.30) | ||
| Trans masculine | 33 (3.89) | 17 (4.37) | 16 (3.48) | 16 (3.70) | 17 (4.08) | ||
| Age (years) | |||||||
| 18–29 | 437 (51.47) | 213 (54.76) | 224 (48.70) | <0.001*** | 243 (56.25) | 194 (46.54) | <0.001*** |
| 30–39 | 249 (29.33) | 129 (33.16) | 120 (26.09) | 137 (31.71) | 112 (26.86) | ||
| 20–49 | 112 (13.19) | 39 (10.03) | 73 (15.87) | 42 (9.72) | 70 (16.79) | ||
| 50+ | 51 (6.01) | 8 (2.06) | 43 (9.35) | 10 (2.31) | 41 (9.83) | ||
| Education attained | |||||||
| Less than college | 177 (20.97) | 95 (24.48) | 82 (17.98) | 0.021* | 112 (25.99) | 65 (15.74) | <0.001*** |
| Some college or more | 667 (79.03) | 293 (75.52) | 374 (82.02) | 319 (74.01) | 348 (84.26) | ||
| Socioeconomic level status | |||||||
| Lower | 127 (14.99) | 79 (20.31) | 48 (10.48) | <0.001*** | 87 (20.19) | 40 (9.62) | <0.001*** |
| Middle | 683 (80.64) | 293 (75.32) | 390 (85.15) | 323 (74.94) | 360 (86.54) | ||
| Upper | 37 (4.37) | 17 (4.37) | 20 (4.37) | 21 (4.87) | 16 (3.85) | ||
| WHO region | |||||||
| Europe | 382 (46.30) | 189 (49.74) | 193 (43.37) | <0.001*** | 224 (53.21) | 158 (39.11) | <0.001*** |
| South-East Asia | 215 (26.06) | 64 (16.84) | 151 (33.93) | 64 (15.20) | 151 (37.38) | ||
| Americas | 81 (9.82) | 48 (12.63) | 33 (7.42) | 46 (10.93) | 35 (8.66) | ||
| Eastern Mediterranean | 76 (9.21) | 47 (12.37) | 29 (6.52) | 48 (11.40) | 28 (6.93) | ||
| Western Pacific | 40 (4.85) | 16 (4.21) | 24 (5.39) | 21 (4.99) | 19 (4.70) | ||
| Africa | 31 (3.76) | 16 (4.21) | 15 (3.37) | 18 (4.28) | 13 (3.22) | ||
| Immigrant status | |||||||
| Yes | 103 (12.32) | 53 (13.84) | 50 (11.04) | 0.352 | 62 (14.62) | 41 (9.95) | 0.075 |
| No | 662 (79.19) | 295 (77.02) | 367 (81.02) | 323 (76.18) | 339 (82.28) | ||
| Unsure | 71 (8.49) | 35 (9.14) | 36 (7.95) | 39 (9.20) | 32 (7.77) | ||
| Natural environmental-level variable | |||||||
| COVID-19 pandemic environment | |||||||
| Ever lack masked | |||||||
| Yes | 112 (13.22) | 69 (17.74) | 43 (9.39) | <0.001*** | 76 (17.59) | 36 (8.67) | <0.001*** |
| No | 735 (86.78) | 320 (82.26) | 415 (90.16) | 356 (82.41) | 379 (91.33) | ||
| In a stay-at-home order | |||||||
| Yes | 651 (76.86) | 299 (77.06) | 352 (76.69) | 0.898 | 326 (75.64) | 325 (78.12) | 0.391 |
| No | 196 (23.14) | 89 (22.94) | 107 (23.31) | 105 (24.36) | 91 (21.88) | ||
| Social/Community-level variables | |||||||
| Socioeconomic loss impact | |||||||
| Reduced income (anticipated) | |||||||
| Yes | 607 (72.87) | 278 (72.77) | 329 (72.95) | 0.955 | 315 (74.12) | 292 (71.57) | 0.408 |
| No | 226 (27.13) | 104 (27.23) | 122 (27.05) | 110 (25.88) | 116 (28.43) | ||
| Job loss/Unemployment (anticipated) | |||||||
| Yes | 132 (15.64) | 86 (22.11) | 46 (10.11) | <0.001*** | 87 (20.19) | 45 (10.90) | <0.001*** |
| No | 712 (84.36) | 303 (77.89) | 409 (89.89) | 344 (79.81) | 368 (89.10) | ||
| Insurance loss (anticipated) | |||||||
| Yes | 99 (16.39) | 57 (21.27) | 42 (12.50) | 0.004** | 63 (20.59) | 36 (12.08) | <0.005** |
| No | 505 (83.61) | 211 (78.73) | 294 (87.50) | 243 (79.41) | 262 (87.92) | ||
| Cutting meals | |||||||
| Yes | 299 (37.52) | 189 (51.50) | 110 (25.58) | <0.001*** | 201 (49.63) | 98 (25.00) | <0.001*** |
| No | 498 (62.48) | 178 (48.50) | 320 (74.42) | 204 (50.37) | 294 (75.00) | ||
| Reduction in gender affirmation services | |||||||
| Hormone therapy† (n=346) | |||||||
| Yes | 115 (33.24) | 70 (45.75) | 45 (23.32) | <0.001*** | 78 (46.99) | 37 (20.56) | <0.001*** |
| No | 231 (66.76) | 83 (54.25) | 148 (76.68) | 88 (53.01) | 143 (79.44) | ||
| Surgical aftercare† (n=318) | |||||||
| Yes | 99 (31.13) | 53 (39.55) | 46 (25.00) | 0.006** | 59 (40.97) | 40 (22.99) | 0.001** |
| No | 219 (68.87) | 81 (60.45) | 138 (75.00) | 85 (59.03) | 134 (77.01) | ||
| Cosmetic supplies and services† (n=459) | |||||||
| Yes | 168 (36.60) | 93 (46.27) | 75 (29.07) | <0.001*** | 102 (45.54) | 66 (28.09) | <0.001*** |
| No | 291 (63.40) | 108 (53.73) | 183 (70.93) | 122 (54.46) | 169 (71.91) | ||
| Mental health counselling† (n=407) | |||||||
| Yes | 168 (41.28) | 96 (52.46) | 72 (32.14) | <0.001*** | 102 (51.26) | 66 (31.73) | <0.001*** |
| No | 239 (58.72) | 87 (47.54) | 152 (67.86) | 97 (48.74) | 142 (68.27) | ||
| Body modifiers† (n=402) | |||||||
| Yes | 134 (33.33) | 75 (42.86) | 59 (25.99) | <0.001*** | 85 (44.50) | 49 (23.22) | <0.001*** |
| No | 268 (66.67) | 100 (57.14) | 168 (74.01) | 106 (55.50) | 162 (76.78) | ||
Column percentages are reported. Sample sizes stratified by variables may not add up to total sample size due to missingness.
*P<0.05, **p<0.01, ***p<0.001.
†Applicable to participants who received gender affirmation services prior to COVID-19 pandemic.
Trans, transgender.
Descriptive statistics and reliabilities of scored variables (n=849)
| Poor mental health | M | SD | Range | Reliability* |
| Anxiety | 1.47 | 1.06 | 0–3 | 0.85 |
| Depression | 1.39 | 1.09 | 0–3 | 0.83 |
M=mean.
*Cronbach’s α.
Figure 2Final adjusted and standardised structural equation model with two mediational analyses. Model ran under 100 bootstrap iterations. Error variance terms for measured variables are shown as ε. Model is adjusted for gender identity, age, migrant status, WHO region, education and level of socioeconomic status. The final model’s χ2 test was=χ2(132)=259.72, p<0.001. With exception to comparative fit index (CFI) and TLI fit indices, this model has an acceptable fit: CFI=0.84, TLI=0.81, root mean square error approximation=0.07, standardised root mean square residual=0.07). *P<0.05, **p<0.01, ***p<0.001.